Nabil F. Saba

Last updated
Nabil F. Saba
Saba Nabil.jpg
Alma mater
Awards
  • Received Distinguished Doctor (2015) [1]
Scientific career
Institutions Emory University
Website

Nabil F. Saba is an American oncologist. He is currently Professor and Vice-chair of Hematology and Medical Oncology, and Professor of Otolaryngology at the Winship Cancer Institute at the Emory University School of Medicine in Atlanta, Georgia. [2] He is a specialist in the field of head and neck oncology. Saba has authored more than 200 peer-reviewed articles. [3] He is the inaugural Lynne and Howard Halpern Chair in Head and Neck Cancer Research. [4]

Contents

Saba is an elected member of the American Head and Neck Society (AHNS) [3] and also specializes in immunotherapy for head and neck cancer, and T cell and B cell activation related to HPV-positive disease. [5] [6]

Saba's work focused on translational research and the study and development of novel therapeutic agents and modalities in the head, neck, and esophageal cancer. He led several clinical trials and chaired national and investigator-initiated multi-institution studies focused on novel approaches for treating these diseases. He is also the editor of two published textbooks, Sinonasal and Skull Base Malignancies and Esophageal Cancer, prevention, diagnosis, and therapy. [3]

Research and career

Nabil Saba earned a B.S. in chemistry at the American University of Beirut in Lebanon, completed his medical degree from the American University of Beirut Medical School. [4]

Saba's research focused on targeting the epithelial growth factor receptor and related pathways in head and neck cancer and immunotherapy approaches for this disease. He investigated the role of related receptors such as HER3 and the mTOR pathway in treating advanced head and neck cancers. He also researched the role of chemoprevention in head and neck cancers. Saba is a national leader in cooperative group trials and chairs two NCTN studies within the ECOG-ACRIN cooperative group, EA3161 and EA3163.[6]

Among Saba's research is the examination of the role of targeting H-Ras in combination with EGFR inhibition in non-HRas mutated head and neck squamous cell cancers. [7] [8]

Saba researched the relationship between radiation dose and overall survival in cervical esophageal cancer. [9] [10] He also conducted research on the peritumoral vasculature in head and neck cancer, revealing that patients with metastatic disease were more likely to have high peritumoral blood microvessel density (MVD). [11]

Saba has been the director of house staff education program at the Winship Cancer Institute of Emory University. [12] He co-directed the head and neck cancers multi-disciplinary program and directed the Head and Neck Medical Oncology Program. [13] [14]

Saba was an assistant professor in the Department of Hematology and Oncology, and served as the director of house staff education programs at the Winship Cancer Institute of Emory University. [12] During his tenure at Emory University School of Medicine, he has served in different positions including Hematology and Medical oncology Professor, Otolaryngology Professor, also lending his services at the Winship Cancer Institute of Emory University as the director of the Head and Neck Medical Oncology Program. [13] [14]

Memberships and awards

Saba won numerous awards including: [15] [16] [17]

Saba is a member of numerous professional organizations including the American College of Radiology, American College of Physicians, American Society of Clinical Oncology, and Massachusetts Medical Society. [18]

Publications

References

  1. ↑ "Naba Sabil". emory.edu.
  2. ↑ "Profile | Emory School of Medicine". med.emory.edu. Retrieved 2019-10-23.
  3. 1 2 3 "Nabil Saba - Google Scholar Citations". scholar.google.com. Retrieved 2019-10-23.
  4. 1 2 "emory.edu". whsc.emory.edu. Retrieved 2019-10-23.
  5. ↑ Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC, Griffith CC, Wang X, Chen ZG, Kissick HT, Saba NF, Ahmed R (September 2021). "Defining HPV-specific B cell responses in patients with head and neck cancer". Nature. 597 (7875): 274–278. doi:10.1038/s41586-020-2931-3. PMC   9462833 . PMID   33208941.
  6. ↑ Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, Nasti TH, Griffith CC, Im SJ, Wang X, Shin DM, Carrington M, Chen ZG, Sidney J, Sette A, Saba NF, Wieland A, Ahmed R (September 2021). "Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer". Nature. 597 (7875): 279–284. Bibcode:2021Natur.597..279E. doi:10.1038/s41586-021-03862-z. PMC   10201342 . PMID   34471285. S2CID   237387748.
  7. ↑ Shu L, Wang D, Nannapaneni S, Sun Y, Griffith CC, Wang X, Chen Z, Patel M, El-Deiry M, Shin DM, Chen ZG, Saba NF (November 2021). "Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)". Oral Oncol. 122 105546. doi:10.1016/j.oraloncology.2021.105546. PMID   34700281. S2CID   239983649.
  8. ↑ Saba NF, Dinasarapu AR, Magliocca KR, Dwivedi B, Seby S, Qin ZS, Patel M, Griffith CC, Wang X, El-Deiry M, Steuer CE, Kowalski J, Shin DM, Zwick ME, Chen ZG (2020). "Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC)". PLOS ONE. 15 (9) e0238497. Bibcode:2020PLoSO..1538497S. doi: 10.1371/journal.pone.0238497 . PMC   7521680 . PMID   32986729.
  9. ↑ Saba, N.; Sutton, D. M.; Ross, H. J.; Siu, S.; Crump, R. M.; Keating, A.; Stewart, A. K. (October 1999). "High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant". Bone Marrow Transplantation. 24 (8): 853–855. doi: 10.1038/sj.bmt.1702005 . ISSN   1476-5365. PMID   10516696.
  10. ↑ Patel, P. R.; McDonald, M. W.; Aiello, A.; Liu, Y.; Saba, N. F.; Beitler, J. J.; Higgins, K. A. (2017-10-01). "The Relationship Between Radiation Dose And Overall Survival In Cervical Esophageal Cancer: An NCDB Analysis". International Journal of Radiation Oncology, Biology, Physics. 99 (2): E178–E179. doi: 10.1016/j.ijrobp.2017.06.1029 . ISSN   0360-3016.
  11. ↑ Evans, Michael; Baddour, Harry Michael Jr.; Magliocca, Kelly R.; Müller, Susan; Nannapaneni, Sreenivas; Chen, Amy Y.; Kim, Sunjin; Chen, Zhengjia; Shin, Dong M.; Wang, Andrew Y.; Saba, Nabil F. (2019). "Prognostic implications of peritumoral vasculature in head and neck cancer". Cancer Medicine. 8 (1): 147–154. doi:10.1002/cam4.1910. ISSN   2045-7634. PMC   6346230 . PMID   30575303.
  12. 1 2 "emory.edu". whsc.emory.edu. Retrieved 2019-10-23.
  13. 1 2 "Dr. Nabil F Saba, MD, FACP - Atlanta, GA - Medical Oncology - Request Appointment". providers.emoryhealthcare.org. Retrieved 2019-10-23.
  14. 1 2 "Nabil F. Saba, MD, FACP". winshipcancer.emory.edu. Retrieved 2019-10-23.
  15. ↑ "Nabil F. Saba, M.D. - Noticed". noticed.co. Archived from the original on 2019-10-24. Retrieved 2019-10-23.
  16. ↑ "Profile | Emory School of Medicine". med.emory.edu. Retrieved 2019-10-23.
  17. ↑ "Nabil F. Saba, MD, FACP". winshipcancer.emory.edu. Retrieved 2019-10-23.
  18. ↑ "Dr. Nabil F Saba, MD, FACP - Atlanta, GA - Medical Oncology - Request Appointment". providers.emoryhealthcare.org. Retrieved 2019-10-23.
  19. ↑ Saba, N.; Sutton, D. M.; Ross, H. J.; Siu, S.; Crump, R. M.; Keating, A.; Stewart, A. K. (1999). "High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant". Bone Marrow Transplantation. 24 (8): 853–855. doi: 10.1038/sj.bmt.1702005 . ISSN   1476-5365. PMID   10516696.
  20. ↑ Saba, Nabil F.; Goodman, Michael; Ward, Kevin; Flowers, Chris; Ramalingam, Suresh; Owonikoko, Taofeek; Chen, Amy; Grist, William; Wadsworth, Trad; Beitler, Jonathan J.; Khuri, Fadlo R. (2011). "Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis". Oncology. 81 (1): 12–20. doi:10.1159/000330807. ISSN   0030-2414. PMC   3186716 . PMID   21912193.
  21. ↑ Saba, Nabil F.; Hurwitz, Selwyn J.; Kono, Scott A.; Yang, Chung S.; Zhao, Yang; Chen, Zhengjia; Sica, Gabe; Müller, Susan; Moreno-Williams, Rachel; Lewis, Melinda; Grist, William (March 2014). "Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study". Cancer Prevention Research (Philadelphia, Pa.). 7 (3): 283–291. doi:10.1158/1940-6207.CAPR-13-0215. ISSN   1940-6215. PMC   4351876 . PMID   24085777.
  22. ↑ Saba, Nabil F.; Wang, Xu; Müller, Susan; Tighiouart, Mourad; Cho, Kwangjae; Nie, Shuming; Chen, Zhuo (Georgia); Shin, Dong M. (2009). "Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug". Head & Neck. 31 (4): 475–481. doi:10.1002/hed.21003. ISSN   1097-0347. PMC   2658731 . PMID   19072997.
  23. ↑ Saba, Nabil F.; Choi, Misun; Muller, Susan; Shin, Hyung Ju C.; Tighiouart, Mourad; Papadimitrakopoulou, Vassiliki A.; El-Naggar, Adel K.; Khuri, Fadlo R.; Chen, Zhuo Georgia; Shin, Dong M. (2009). "Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma". Cancer Prevention Research (Philadelphia, Pa.). 2 (9): 823–829. doi:10.1158/1940-6207.CAPR-09-0077. ISSN   1940-6215. PMC   2910364 . PMID   19737986.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.